Today's Must Read
Core Commerce & Cloud Business Strength Aids Alibaba (BABA)
J&J's (JNJ) Pharma Unit, COVID-19 Vaccine Key to 2021 Growth
Thursday, June 24, 2021
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Alibaba Group (BABA), and Johnson & Johnson (JNJ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Tesla have underperformed the Zacks Domestic Automotive industry in the year-to-date period (-2.4% vs. +0.5%). The Zacks analyst, however, believes that the company has a first-mover advantage in the e-mobility space, with high range vehicles, superior technology and software edge.
Further, robust demand for Model 3/Y, Shanghai Gigafactory prospects, and aggressive expansion efforts bode well for the firm. However, an unclear 2021 vehicle delivery target is a cause of concern. Moreover, Tesla’s high operating costs and massive capex due to heavy investments related to the construction of gigafactories as well as the development of battery tech are likely to weigh on its near-term financials.
Alibaba’s shares have lost -1.8% over the last six months against the Zacks Internet Commerce industry’s loss of -18.1%. However, the Zacks analyst thinks that Alibaba has been benefiting from solid momentum across the Core Commerce segment on the back of growth in its China and International Commerce businesses.
Also, its robust New Retail strategy which is gaining traction in the market is another positive. Additionally, the company’s strengthening cloud business on the back of its expanding customer base continues to drive its performance. However, regulatory concerns and higher costs associated with new initiatives remain major problems for the company.
Shares of Johnson & Johnson have gained +1.3% in the past three months against the Zacks Large Cap Pharmaceuticals industry’s gain of +9.5%. The Zacks analyst is impressed by J&J’s resilience amid the current macroeconomic turmoil, which it believes is due to the company’s diversification efforts.
Further, its Pharma unit is performing at above-market levels, supported by increased penetration of drugs such as Imbruvica, Darzalex and Stelara. J&J is also making rapid progress with its pipeline and line extensions with several pivotal data readouts lined up in 2021. However, J&J faces numerous lawsuits, which allege personal injuries to patients caused by the use of its products.
Other noteworthy reports we are featuring today include Toyota Motor (TM), 3M Company (MMM) and Colgate-Palmolive (CL).
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>